Depression

 

 

Clinical trail of estrogen tablet trial for women of child bearing age, with schizophrenia or shcizoaffective disorder. To take part in this study you must be physically well, have a diagnosis of depression, be perimenopausal and able to give informed consent.

For further details click here or contact Emmy Gavrilidis on 9076 6913 or email e.gavrilidis@alfred.org.au

 

 

Clinical trail of oxytocin nasal spray and an estrogen tablet, for women experiencing treatment resistant depression. To take part in this study you must be female, physically well, have a diagnosis of depression, be between the ages of 18-45 and able to give informed consent.For further details click here or contact Dr Charlotte Keating on 9076 5180 or email c.keating@alfred.org.au   

 

 

TMS uses magnetic pulses to change activity in the areas of the brain thought to be related to this illness, and is being investigated as an alternative treatment for people, who have not responded to antidepressant medication, are experiencing the depressive phase of bipolar disorder, or who developed depression following a head injury.For further information click here or contact Dr. Sally Herring on 9076 6596 or email s.herring@alfred.org.au   

 

 

MST uses a magnetic field to induce a seizure for therapeutic purposes, and is being investigated as an alternative to Electroconvulsive therapy for severe depression.For further information click here or contact Dr. Kate Hoy on 9076 5034 or email k.hoy@alfred.org.au    

 

 

Deep Brain Stimulation involves the precise implantation of very small electrodes into specific areas of the brain, in an attempt to change activity in those and related areas and improve the symptoms of very severe, treatment resistant depression.For further information click here or contact Dr. Rebecca Segrave on 9076 3245 or email r.segrave@alfred.org.au 

 

 

A new technique, EVestG (ElectrovestibuloGraphy) in being investigated as a possible objective method for diagnosing participants with depression.For further information click here or contact Juliana Mitchell-Wong on 9076 5033 or email juliana.mitchell-wong@monash.edu  

 

 

Little is known about how to treat depression and most depressed individuals often take a number of medications to find out which medication best suits them. iSPOT-D is a large international study to find out who will respond to which antidepressant. The principal aim is to get the prescription right the first time. You may be eligible if you are aged 18–65 and have already been diagnosed or suspect you have depression. The study involves two testing sessions and seven telephone check-ins within 12 months. You will also provide a blood sample to the researchers and receive treatment from you own doctor. Participants will be reimbursed for their time.  For further information click here or contact Niharika Anand on 9076 8045 or email n.anand@alfred.org.au   

 

 

An observational study of women taking / not taking hormonal contraception (i.e. COCP, POP, Implanon, DMPA) exploring current mood & risk and resistance factors for adverse mood change.   To take part in this study you must be a female 18 years of age or older, able to give informed consent and not currently pregnant, breast-feeding or menopausal.For further information click here or contact Emmy Gavrilidis on 9076 6913 or email e.gavrilidis@alfred.org.au  

 

 

An observational study for women who are taking or have taken antipsychotic medications during their pregnancy.For further information click here or contact Heather Gilbert 9076 6591 or email h.gilbert@alfred.org.au  

 

 

A study evaluating an investigational drug that is intended to be taken with your current antidepressant (SSRI), to see if it helps lesson any ongoing symptoms of depression.   For further information click here or contact Mr. Scott Santinon on 9076 6589 or email s.santinon@alfred.org.au

 

 

A neuroimaging study using functional magnetic resonance imaging (fMRI) and electroencephalography (EEG), in conjunction with cognitive testing and blood biomarkers, to look at the emotional brain function and neurological health in depression. For further information click here or contact Peter Goodin on 0425 798 610 or email pgoodin@swin.edu.au